1. Introduction {#sec1}
===============

Frontotemporal lobar degeneration (FTLD) is a common neurodegenerative disease that usually affects people in midlife ([@bib15]). It is clinically heterogenous with 3 main subtypes: behavioral variant frontotemporal dementia (bvFTD), progressive nonfluent aphasia, and semantic dementia. It is also pathologically heterogenous with about 50% of cases showing neuronal cytoplasmic inclusions consisting of hyperphosphorylated tau protein. Approximately 45% of cases have neuronal cytoplasmic inclusions that lack tau, but instead contain the DNA- and RNA-binding protein TDP-43. The remaining 5% cases have inclusions that consist of another DNA- and/or RNA-binding protein, fused in sarcoma ([@bib8]).

Up to 40% of patients with FTLD present with a family history of this disease and in some instances also with amyotrophic lateral sclerosis (ALS). Much progress in the understanding of the genetic basis of FTLD has been made in the past 15 years, with 3 main genes causing autosomal dominant forms of disease having been identified. These are tau gene ([@bib6]), progranulin ([@bib3]), and most recently a hexanucleotide repeat expansion in *C9orf72* ([@bib5; @bib14]), the latter being the most common genetic cause of FTLD and ALS identified to date. Despite being extremely large, sometimes over 20 kb, the expansion is relatively easy to genotype using repeat-primed polymerase chain reaction (PCR). This method has been widely used to establish the frequency of the expansion in populations worldwide ([@bib9]). In addition, this methodology is presently used in a clinical genetics setting to aid diagnosis of FTLD and ALS. The expansion has been shown to be the most common in Northern European populations, probably because of a founder effect ([@bib12]). Currently, 3 potential mechanisms have been proposed by which the expansion leads to disease, these being haploinsufficiency, toxic RNA in the form of nuclear foci, and dipeptide-repeat proteins (DPR) which are repeat associated non-ATG translated from the expansion ([@bib2; @bib13]).

When establishing the presence and frequency of the *C9orf72* repeat expansion in our own clinical and autopsy patient cohorts with various diseases, we detected 2 patients (brothers, one with bvFTD and the other ALS) that were positive for DPR pathology in both cerebral cortex and cerebellum ([Supplementary Fig. 1](#appsec1){ref-type="sec"}) but had no expansion when tested with repeat-primed PCR. Despite repeated re-extraction of DNA from both blood and brain tissues in both patients, we could not detect more than 6 repeats using previously published repeat-primed PCR ([@bib14]). Consequently, a Southern blot was performed with DNA extracted from brain tissue. This showed both patients had an expansion of approximately 1500--3000 repeats. As the repeat-primed PCR methodology is currently being used in a clinical genetics setting to diagnose disease presence in patients and to test family members for disease risk, it is vital that such methodology is robust in providing a correct genotype. Here, we describe the characterization of the C9orf72 expansion in these 2 patients to understand why we were unable to detect the expansion when using previously validated repeat-primed PCR ([@bib14]).

2. Methods {#sec2}
==========

All FTLD patients known to harbor a proven mutation *MAPT* or *GRN* were excluded, as were those cases that displayed tau pathology at postmortem. The final study group comprised 460 patients (mean age at onset, 60 years; range, 24--83 years), 244 men (mean age at onset, 60 years; range, 34--81 years), and 181 women, (mean age at onset, 59 years; range, 23--83 years). Control cases were drawn from healthy spouse, 253 being male (mean age, 56 years; range, 30--79 years) and 397 female (mean age, 53 years; range, 26--81 years). The London cohort consisted of 367 cases of FTLD (41% female, average onset of 59). All patients and control subjects were of UK Caucasian ethnic origin and were recruited with ethical committee approval and provided informed consent.

A bacterial artificial chromosome (BAC) library was constructed, from cerebellar tissue from the case of bvFTD described in the introduction, by Bio S&T Inc (Canada) using the pIndigoBAC-5 vector. This was screened to isolate a BAC clone that contained C9orf72, and the expansion. Sanger sequencing was performed using BigDye v3 (Applied Biosystems) run on an ABI 3730 (Applied Biosystems). One microgram of BAC DNA was included in each reaction along with 10 pm of primer, 8 μL of BigDye sequencing master mix v3.1 (Applied Biosystems) in a total volume of 40 μL. When used, DMSO was added, it was at a final concentration of 6% and betaine at 1 M. Ion torrent next generation sequencing was performed according to the manufacturer\'s instructions (Life Technology). Southern blot and repeat-primed PCR were performed as previously described ([@bib11; @bib14]).

3. Results {#sec3}
==========

Our initial thoughts which might explain our inability to detect an expansion in these 2 brothers was that there was an single nucleotide polymorphism under the primer used for repeat-primed PCR that lay outside of the expansion. However, we sequenced this region which was wild type in both patients (not shown). An expansion in *C9orf72* was confirmed by Southern blotting in both brothers ([Fig. 1](#fig1){ref-type="fig"}). To elucidate as to why the repeat-primed PCR did not detect this, we attempted to sequence the BAC clone of *C9orf72* with the expansion we had obtained. When we used standard Sanger sequencing with a primer placed on the telomeric side of the expansion, we obtained good sequence data that read through some of the expansion and confirmed it was the usual GGGGCC hexanucleotide repeat ([Supplementary Fig. 2](#appsec1){ref-type="sec"}). This also proved that the expansion was not GC clamping the BAC and preventing polymerase read through. However, when we placed a primer on the centromeric side of the repeat and sequenced toward it, the reaction consistently failed to produce any sequence data, even when we placed a primer up to 1 kb away. After ruling out issues of DNA purity, we attempted to use next generation sequencing (Ion Torrent Personal Genome Machine) to sequence the entire BAC. We obtained around a 70-fold read depth for the entire BAC apart from the repeat region where coverage was low, particularly on the centromeric side. Analysis of this data did not reveal any differences to the reference genome, Primary Assembly (GRCh38). Given that Sanger sequencing produced good reads from the telemetric side of the expansion, but not from the centromeric side, we hypothesized that a variation in the sequence in this part of *C9orf72* was producing a secondary structure that was preventing sequencing polymerase read through. We therefore attempted a Sanger sequencing reaction with high levels of DNA denaturants (1 M betaine and 6% DMSO). This produced a good sequence and when compared with the reference genome (GRCh38 Primary Assembly), we were able to detect a 10 bp deletion directly adjacent to the start of the repeat ([Fig. 2](#fig2){ref-type="fig"}). This 10 bp section contains some AT sequence, and when removed the repeat is then adjacent to more GC rich sequence.

Previously, we had been using the assay of [@bib14] to genotype our FTLD and control cohorts and had identified 37 expansion carriers in the FTLD group. When we repeated the genotyping using the assay of [@bib5] (which should not be affected by the presence of the deletion; [Fig. 3](#fig3){ref-type="fig"}) we detected a further 11 cases, an increase of approximately 25%. In addition, we genotyped our ALS cohort (n = 234) and the number of expansion carriers increased from 16 to 20 ([Table 1](#tbl1){ref-type="table"}). However, repeated analysis of previously screened London FTLD cohort failed to detect any additional cases.

In a recent study, [@bib7] reported that residual genetic association to chromosome 9p remained, even when known expansion carriers were removed from their ALS cohort. When we performed this same analysis in our cohort using rs10967976 following removal of old and newly identified expansion carriers, previous residual association was completely abolished ([Table 2](#tbl2){ref-type="table"}).

4. Discussion {#sec4}
=============

DRP inclusions are thought to be specific to *C9orf72* expansion carriers; however, there has been some controversy as to their role in the neurodegenerative process ([@bib10]). Nevertheless, they could be considered the equivalent of amyloid plaques in Alzheimer\'s disease with TDP-43 inclusions being the equivalent neurofibrillary inclusions, and this may account for the discrepancy of DPR distribution and neurodegeneration. Our neuropathologic analyses of the brains of the 2 brothers showing DPR inclusions, when no such expansion had been found using PCR methodology, lead us to reanalyze these cases in depth. Indeed, Southern blotting revealed an expansion that was undetectable using our standard assay ([@bib14]). Subsequently, however, such an expansion became detectable using the assay of [@bib5]. These observations highlight to need to consider to what extent genetic variation can affect PCR-based assays and reenforces the utility of relevant neuropathologic investigation. Sequencing of a BAC cloned from genomic DNA from one of the individuals identified a 10 bp deletion adjacent to the repeat region. A 10 base deletion at this region has been reported previously but with a normal nonexpanded GGGGCC repeat ([@bib16]). However, the deleted sequence reported by [@bib16] is reversed when compared with the sequence in the current genome Primary Assembly (GRCh38). Investigation of alternative assemblies in the genome databases reveals some heterogeneity at this locus which could explain these differences. Standard Sanger sequencing failed to read through the area containing the deletion in the BAC, and sequence data were only obtained when strong DNA denaturants were included into the reaction. Presumably, the deletion confers a strong secondary structure in the region that prevents polymerase read through. Although denaturants are also included into the repeat-primed PCR assay, the wild-type allele still gets preferentially amplified and dominates over the mutant.

Using the assay of [@bib5], we could bypass issues of the deletion affecting genotyping, and in so doing increased the number of expansion carriers in our cohort by approximately 25%. There were not any robust clinical differences between the newly identified cases and those previously identified. Nonetheless, other previously undetected carriers were not identified in the London cohort, suggesting that the deletion in combinations with the expansion could be geographically specific. The study reported by [@bib7], reporting residual association in *C9orf72* following removal of known expansion carriers, paradoxically claimed to use the assay of [@bib5] and therefore should not have been affected by the 10 bp deletion. However, it is possible there is other genetic variation on the other side of the expansion affecting this assay, with expansion carriers bearing such a variation again being missed, and this explaining the residual association. Clearly, local founder effects do occur as we only find the 10 bp deletion with an expansion on the same haplotype in cases from the North West of England all of which could theoretically be distantly related. However, further genotyping is required to fully establish whether this is the case. Moreover, there has been a recent report of major inconsistencies in correctly genotyping cases of known expansion by different laboratories using local methodologies ([@bib1]). This observation has important implications for patients undergoing genetic testing for *C9orf72*, and we would recommend genotyping samples with both Renton and DeJesus-Hernandez PCR-based methods to ensure that expansion carriers do not go undetected.
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![Southern blot (as of [@bib9] for Set A and [@bib4] for Set B) of C9orf72 of both brothers confirming a repeat expansion is present in both. Set A left to right, marker; negative control, positive control, patient samples. Set (B) left to right; marker; patient samples; positive control; negative control.](gr1){#fig1}

![Ten bp deletion adjacent to the GGGGCC repeat region.](gr2){#fig2}

![Top--repeat primed PCR showing 6 repeats in C9orf72 using the assay by [@bib13] in a case with the 10 bp deletion. Bottom--the same case genotyped with the assay by [@bib4] showing the expansion also shown by Southern blot. Abbreviation: PCR, polymerase chain reaction.](gr3){#fig3}

###### 

rs10967976 genotype analysis in the Manchester FTLD cohort

  rs10967976                             Controls (%)   FTD all (%)   OR     95% CI       *p*     FTD and/or MND (%)   OR     95% CI       *p*
  -------------------------------------- -------------- ------------- ------ ------------ ------- -------------------- ------ ------------ -------
  All cases                                                                                                                                
  AA                                     164 (26.54)    106 (24.20)   1.0    ---                  11 (16.92)           1.0    ---          
  GA                                     330 (53.40)    217 (49.54)   1.01   0.75--1.37   0.91    34 (52.31)           1.53   0.75--3.10   0.233
  GG                                     124 (20.06)    115 (26.26)   1.43   1.00--2.04   0.045   20 (30.77)           2.40   1.11--5.20   0.026
  GA + GG                                454 (73.46)    332 (75.80)   1.13   0.85--1.50   0.86    54 (83.08)           1.77   0.90--3.47   0.095
  AA + GA                                494 (79.94)    323 (73.74)   1.0    ---                  45 (69.23)           1.0                 
  GG                                     124 (20.06)    115 (26.26)   1.42   1.06--1.89   0.016   20 (30.77)           1.81   1.00--3.10   0.046
  Drop "old" expansion cases                                                                                                               
   AA                                    164 (26.54)    103 (25.69)   1.0                         11 (21.15)           1.0                 
   GA                                    330 (53.40)    200 (49.88)   0.96   0.71--1.30   0.817   25 (48.08)           1.12   0.54--2.35   0.745
   GG                                    124 (20.06)    98 (24.44)    1.26   0.87--1.80   0.213   16 (30.77)           1.92   0.86--4.29   0.110
   GA + GG                               454 (73.46)    298 (74.31)   1.04   0.78--1.39   0.763   41 (78.85)           1.34   0.67--2.68   0.398
   AA + GA                               494 (79.94)    303 (75.56)   1.0                         36 (69.23)           1.0                 
   GG                                    124 (20.06)    99 (24.44)    1.28   0.95--1.74   0.099   16 (30.77)           1.77   0.95--3.29   0.071
  Drop "old" and "new" expansion cases                                                                                                     
   AA                                    164 (26.54)    100 (25.64)   1.0                         10 (20.41)           1.0                 
   GA                                    330 (53.40)    198 (50.77)   0.98   0.72--1.33   0.917   25 (51.02)           1.24   0.58--2.64   0.574
   GG                                    124 (20.06)    92 (23.59)    1.21   0.84--1.75   0.295   14 (28.57)           1.85   0.79--4.30   0.153
   GA + GG                               454 (73.46)    290 (74.36)   1.04   0.78--1.39   0.768   39 (79.59)           1.40   0.68--2.88   0.349
   AA + GA                               494 (79.94)    298 (76.41)   1.0                         35 (71.43)           1.0                 
   GG                                    124 (20.06)    92 (23.59)    1.22   0.90--1.66   0.184   14 (28.57)           1.59   0.83--3.20   0.160

Key: CI, confidence interval; FTD, frontotemporal dementia; FTLD, frontotemporal lobar degeneration; OR, odds ratio.

###### 

Frequencies of the original and newly identified C9orf72 expansion carriers in the Manchester cohort

  Cases               C9 carriers old   C9 carriers new   C9 carriers total
  ------------------- ----------------- ----------------- -------------------
  All FTLD, N = 460   37                11                48
  FTD + ALS, N = 74   12                3                 15
  ALS, N = 234        16                4                 20

Key: ALS, amyotrophic lateral sclerosis; FTLD, frontotemporal lobar degeneration.
